JP2015506363A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506363A5
JP2015506363A5 JP2014552326A JP2014552326A JP2015506363A5 JP 2015506363 A5 JP2015506363 A5 JP 2015506363A5 JP 2014552326 A JP2014552326 A JP 2014552326A JP 2014552326 A JP2014552326 A JP 2014552326A JP 2015506363 A5 JP2015506363 A5 JP 2015506363A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
composition according
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014552326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/021223 external-priority patent/WO2013106702A1/en
Publication of JP2015506363A publication Critical patent/JP2015506363A/ja
Publication of JP2015506363A5 publication Critical patent/JP2015506363A5/ja
Pending legal-status Critical Current

Links

JP2014552326A 2012-01-13 2013-01-11 ハロフジノール誘導体、および化粧料組成物および医薬組成物におけるその使用 Pending JP2015506363A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586271P 2012-01-13 2012-01-13
US61/586,271 2012-01-13
PCT/US2013/021223 WO2013106702A1 (en) 2012-01-13 2013-01-11 Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2015506363A JP2015506363A (ja) 2015-03-02
JP2015506363A5 true JP2015506363A5 (enExample) 2016-03-03

Family

ID=47844437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552326A Pending JP2015506363A (ja) 2012-01-13 2013-01-11 ハロフジノール誘導体、および化粧料組成物および医薬組成物におけるその使用

Country Status (6)

Country Link
US (1) US10155742B2 (enExample)
EP (1) EP2802572B1 (enExample)
JP (1) JP2015506363A (enExample)
AU (1) AU2013207796B2 (enExample)
CA (1) CA2861840C (enExample)
WO (1) WO2013106702A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009282480B2 (en) 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
MY174343A (en) * 2014-06-23 2020-04-09 Dae Woong Pharma Novel heterocyclic compound
KR102277538B1 (ko) 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
JP2019196307A (ja) 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
US20190365760A1 (en) * 2016-11-14 2019-12-05 Keio University A therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative or autoimmune disease, and a hypoxia inducing factor inhibitor
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation PROLYL TRNA SYNTHETASE INHIBITORS
CN109134437B (zh) * 2018-08-24 2021-05-25 中山大学 一种去氧常山酮类化合物及其制备方法和应用
WO2021163304A1 (en) * 2020-02-11 2021-08-19 Tufts Medical Center, Inc. Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
EP4374859A4 (en) * 2021-07-23 2025-03-19 Daewoong Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GENERALIZED SCLERODERMA
WO2023140505A1 (ko) * 2022-01-18 2023-07-27 (주)큐라미스 할로푸지논을 유효성분으로 함유하는 신경퇴행성 또는 운동신경 질환 예방 또는 치료용 조성물
CN114288300B (zh) * 2022-01-29 2023-04-21 中国科学技术大学 常山酮在治疗和预防脂肪肝、肥胖的药物中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694711A (en) 1952-12-02 1954-11-16 American Cyanamid Co Quinazolone antimalarial compounds
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2020234A1 (de) 1970-04-25 1971-11-18 Cassella Farbwerke Mainkur Ag Basisch substituierte Derivate des 4(3H)-Chinazolinons
GB1541463A (en) 1975-10-11 1979-02-28 Lion Dentifrice Co Ltd Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase
DE2934069A1 (de) 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
US4762838A (en) 1985-08-30 1988-08-09 Pfizer Inc. Quinazolin-4(3H)-one derivatives as anticoccidial agents
US4937370A (en) 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US4999186A (en) 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4725599A (en) 1986-09-08 1988-02-16 Pfizer Inc. Heterocyclic ring fused pyrimidine-4 (3H)-ones as anticoccidial agents
US4960764A (en) 1987-03-06 1990-10-02 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
US4800197A (en) 1987-07-17 1989-01-24 Richardson-Vicks Inc. Anti-acne composition
US4891228A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4891227A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US6446032B1 (en) 1990-09-21 2002-09-03 Massachusetts Institute Of Technology Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove
US5073372A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
CA2113229C (en) 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
US5759833A (en) 1994-05-27 1998-06-02 Cubist Pharmaceuticals, Inc. Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
WO1998043642A1 (en) 1997-03-31 1998-10-08 Agricultural Research Organization Treatment for pulmonary fibrosis
DE69927987T2 (de) 1998-08-13 2006-11-09 Hadasit Medical Research Services & Development Co. Ltd. Hemmung von mit gewebetrauma verbundenen pathogenen prozessen
AU6918700A (en) 1999-08-20 2001-03-19 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
JP3771128B2 (ja) 2000-12-28 2006-04-26 独立行政法人科学技術振興機構 フェブリフジンおよびフェブリフジン化合物の新規合成方法
US20050227935A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
AU2002356043A1 (en) 2001-08-14 2003-03-03 Washington University In St. Louis Systems and methods for screening pharmaceutical chemicals
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
CN1263753C (zh) 2004-05-21 2006-07-12 厦门大学 一种合成常山碱与ru－19110中间体的方法
CA2600046A1 (en) * 2005-02-23 2006-08-31 Collgard Biopharmaceuticals Ltd. Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
EP2010136B1 (en) 2006-04-10 2012-09-12 The President and Fellows of Harvard College Methods for modulating formation and progression of cellulite
BRPI0722382A2 (pt) 2006-04-14 2012-06-05 Prana Biotechnology Ltd compostos úteis para o tratamento de cáncer
WO2007147217A1 (en) 2006-06-22 2007-12-27 Prana Biotechnology Limited Method of treatment of glioma brain tumour
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
US20080188498A1 (en) 2007-02-05 2008-08-07 Radix Pharmaceuticals, Inc. Pyridopyrimidinone compounds with antimalarial activity
ES2564826T3 (es) 2007-06-21 2016-03-29 Neuronascent, Inc. Métodos y composiciones para estimular neurogénesis e inhibir degeneración neuronal utilizando isotiazolopirimidinonas
WO2009023267A2 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
US20090123389A1 (en) 2007-08-15 2009-05-14 Malcolm Whitman Methods for modulating Th17 cell development in the treatment and prevention of cellulite
AU2009282480B2 (en) 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US20120058133A1 (en) 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
US8357692B2 (en) * 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions

Similar Documents

Publication Publication Date Title
EP4420732A3 (en) Fused ring heteroaryl compounds and their use as trk inhibitors
JP2015078230A5 (enExample)
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
EP4643945A3 (en) Neuroactive steroids and methods of use thereof
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
JP2013032389A5 (enExample)
JP2014176384A5 (enExample)
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
JP2017537066A5 (enExample)
JP2016540749A5 (enExample)
WO2015130842A3 (en) Ether compounds for treatment of complement mediated disorders
WO2017087608A8 (en) Modulators of ror-gamma
JP2016530259A5 (enExample)
EA201690962A1 (ru) Составы
JP2016540742A5 (enExample)
RU2017128643A (ru) Новое производное хинолина для применения в лечении и профилактике вирусных инфекций
JP2017518982A5 (enExample)
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
JP2015521195A5 (enExample)
HK1220402A1 (zh) 新型环孢菌素衍生物和其用途
JP2015526455A5 (enExample)
RU2018101431A (ru) Ингибиторы индоламин-2,3-диоксигеназы